The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Pharmacokinetics of Bevacizumab after Topical, Subconjunctival, and Intravitreal Administration in Rabbits
Abstract
PURPOSE: To investigate the pharmacokinetics of bevacizumab in rabbits for three different routes of administrations: intravitreal injection, subconjunctival injection, and eye drops. METHODS: Pigmented rabbits received bevacizumab in one eye by topical eye drops (1.25 mg/0.05 mL six times daily for the first 7 days), single subconjunctival injection (1.25 mg/0.05 mL), or single intravitreal injection (1.25 mg/0.05 mL). Bevacizumab concentrations in plasma and ocular tissues in the treated and fellow eyes were determined by sandwich enzyme-linked immunosorbent assay at 1, 2, 4, and 12 weeks after administration. RESULTS: After intravitreal injection in the treated eye, the mean maximum concentrations (C(max)) of bevacizumab in the iris/ciliary body and retina/choroid were 109,192.6, and 93,990.0 ng/g, respectively, whereas after subconjunctival injection, the C(max) was 1418.7 and 295.8 ng/g, respectively. In the fellow eyes, when the drug was administered by intravitreal injection, the C(max) was 753.6 ng/g in the iris/ciliary body and 224.2 ng/g in the retina/choroid and by subconjunctival injection was 1192.9 and 187.0 ng/g, respectively. With eye drops, only a small level of bevacizumab was detected in the iris/ciliary body and retina/choroid. Systemic exposure to bevacizumab was at the same level when administered by intravitreal or subconjunctival injection. CONCLUSIONS: Intravitreal injection of bevacizumab was the most effective route of administration for intraocular tissue. Also, bevacizumab injected subconjunctivally was transported into the intraocular tissues of the treated eyes at an effective level. Both intravitreal and subconjunctival injections of bevacizumab resulted in high plasma concentrations. Bevacizumab was distributed into the intraocular tissues in fellow eyes via the systemic circulation. This treatment may be effective for blocking vascular endothelial growth factor activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Avery, R. L., Pearlman, J., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., Giust, M. J., Wendel, R., & Patel, A. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.064 · Cited by 799
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683
Beer, P. M., Bakri, S. J., Singh, R. J., Liu, W., Peters, G. B., & Miller, M. (2003) · Ophthalmology · doi:10.1016/s0161-6420(02)01969-3 · Cited by 570
Fung, A. E., Rosenfeld, P. J., & Reichel, E. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.099598 · Cited by 532
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
Wang, Y., Fei, D., Vanderlaan, M., & Song, A. (2004) · Angiogenesis · doi:10.1007/s10456-004-8272-2 · Cited by 430
Crystal structure of the complex of rat neonatal Fc receptor with Fc
(1995) · Trends in Genetics · doi:10.1016/0168-9525(95)90005-5 · Cited by 381
Intraocular Pharmacokinetics of Bevacizumab After a Single Intravitreal Injection in Humans
Krohne, T. U., Eter, N., Holz, F. G., & Meyer, C. H. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.05.036 · Cited by 363
(2000) · PubMed · Cited by 358
SHAHAR, J., AVERY, R. L., HEILWEIL, G., BARAK, A., ZEMEL, E., LEWIS, G. P., JOHNSON, P. T., FISHER, S. K., PERLMAN, I., & LOEWENSTEIN, A. (2006) · Retina · doi:10.1097/00006982-200603000-00002 · Cited by 350
REGRESSION OF RETINAL AND IRIS NEOVASCULARIZATION AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT
AVERY, R. L. (2006) · Retina · doi:10.1097/00006982-200603000-00016 · Cited by 342
Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey
Heiduschka, P., Fietz, H., Hofmeister, S., Schultheiss, S., Mack, A. F., Peters, S., Ziemssen, F., Niggemann, B., Julien, S., Bartz-Schmidt, K. U., et al. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-1171 · Cited by 253
CHIN, H.-S., PARK, T.-S., MOON, Y.-S., & OH, J.-H. (2005) · Retina · doi:10.1097/00006982-200507000-00002 · Cited by 242
The Effect of Topical Bevacizumab on Corneal Neovascularization
Kim, S. W., Ha, B. J., Kim, E. K., Tchah, H., & Kim, T.-I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.02.013 · Cited by 239
Bashshur, Z. F., Haddad, Z. A., Schakal, A., Jaafar, R. F., Saab, M., & Noureddin, B. N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.09.031 · Cited by 236
Wakabayashi, T., Oshima, Y., Sakaguchi, H., Ikuno, Y., Miki, A., Gomi, F., Otori, Y., Kamei, M., Kusaka, S., & Tano, Y. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.02.026 · Cited by 217
Complications in patients after intravitreal injection of bevacizumab
Shima, C., Sakaguchi, H., Gomi, F., Kamei, M., Ikuno, Y., Oshima, Y., Sawa, M., Tsujikawa, M., Kusaka, S., & Tano, Y. (2008) · Acta Ophthalmologica · doi:10.1111/j.1600-0420.2007.01067.x · Cited by 200
Rizzo, S., Genovesi-Ebert, F., Di Bartolo, E., Vento, A., Miniaci, S., & Williams, G. (2008) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0774-y · Cited by 195
Transscleral delivery of bioactive protein to the choroid and retina.
Ambati, J., Gragoudas, E. S., Miller, J. W., You, T., Miyamoto, K., Delori, F. C., & Adamis, A. P. (2000) · PubMed · Cited by 187
INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR CENTRAL AND HEMICENTRAL RETINAL VEIN OCCLUSIONS: IBeVO Study
COSTA, R. A., JORGE, R., CALUCCI, D., MELO, L. A., CARDILLO, J. A., & SCOTT, I. U. (2007) · Retina · doi:10.1097/iae.0b013e31802eff83 · Cited by 180
KOOK, D., WOLF, A., KREUTZER, T., NEUBAUER, A., STRAUSS, R., ULBIG, M., KAMPIK, A., & HARITOGLOU, C. (2008) · Retina · doi:10.1097/iae.0b013e318176de48 · Cited by 164
Transscleral drug delivery to the posterior eye: Prospects of pharmacokinetic modeling
Ranta, V.-P., & Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.025 · Cited by 160
Zhu, Q., Ziemssen, F., Henke‐Fahle, S., Tatar, O., Szurman, P., Aisenbrey, S., Schneiderhan‐Marra, N., Xu, X., & Grisanti, S. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.04.023 · Cited by 157
Subconjunctival Bevacizumab Injection for Corneal Neovascularization
Bahar, I., Kaiserman, I., McAllum, P. J., Rootman, D., & Slomovic, A. R. (2008) · Cornea · doi:10.1097/ico.0b013e318159019f · Cited by 147
Robinson, M. R., Lee, S. S., Kim, H., Kim, S., Lutz, R. J., Galbán, C. J., Bungay, P. M., Yuan, P., Wang, N. S., Kim, J., et al. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2005.08.007 · Cited by 142
Intravitreal Bevacizumab for Treatment of Uveitic Macular Edema
Coma, M. C., Sobrin, L., Önal, S., Christen, W., & Foster, C. S. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.11.028 · Cited by 137
Maurice, D. M., & Polgar, J. (1977) · Experimental Eye Research · doi:10.1016/0014-4835(77)90136-1 · Cited by 127
Inhibition of Corneal Neovascularization by Subconjunctival Bevacizumab in an Animal Model
Papathanassiou, M., THEODOSSIADIS, P. G., Liarakos, V. S., ROUVAS, A. A., Giamarellos‐Bourboulis, E. J., & Vergados, I. A. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.11.003 · Cited by 112
Cheruvu, N. P. S., & Kompella, U. B. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-0404 · Cited by 107
Genentech discloses safety concerns over Avastin
Ratner, M. (2004) · Nature Biotechnology · doi:10.1038/nbt1004-1198 · Cited by 101
for the Pan-American Collaborative Retina Study Group (PACORES), Arévalo, J. F., Sánchez, J. G., Fromow-Guerra, J., Wu, L., Berrocal, M. H., Farah, M. E., Cardillo, J. A., & Rodríguez, F. J. (2009) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-1034-x · Cited by 93
de Ávila, M. P., Farah, M. E., Santos, A., Duprat, J. P., Woodward, B. W., & Nau, J. A. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.145912 · Cited by 90
Modeling of Corneal and Retinal Pharmacokinetics after Periocular Drug Administration
Amrite, A. C., Edelhauser, H. F., & Kompella, U. B. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0593 · Cited by 78
Kim, T., Kim, S. W., Kim, S., Kim, T., & Kim, E. K. (2008) · Cornea · doi:10.1097/ico.0b013e31815cf67d · Cited by 77
Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia
Issa, P. C., Finger, R. P., Holz, F. G., & Scholl, H. P. N. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.129627 · Cited by 76
Subconjunctival bevacizumab for vascularized rejected corneal grafts
Awadein, A. R. (2007) · Journal of Cataract & Refractive Surgery · doi:10.1016/j.jcrs.2007.07.012 · Cited by 73
Mapping of the Neonatal Fc Receptor in the Rodent Eye
Kim, H., Fariss, R. N., Zhang, C., Robinson, S. B., Thill, M., & Csaky, K. G. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0871 · Cited by 68
Interaction of Lumican with Aggrecan in the Aging Human Sclera
Dunlevy, J. R., & Rada, J. A. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0496 · Cited by 62
Arévalo, J. F., Fromow-Guerra, J., Sánchez, J. G., Maia, M., Berrocal, M. H., Wu, L., Saravia, M., & Costa, R. A. (2008) · Retina · doi:10.1097/iae.0b013e3181884ff4 · Cited by 60
Pharmaceutical applications of isoelectric focusing on microchip with imaged UV detection
Vlčková, M., Kálmán, F., & Schwarz, M. A. (2007) · Journal of Chromatography A · doi:10.1016/j.chroma.2007.12.046 · Cited by 45
Heiduschka, P., Julien, S., Hofmeister, S., Bartz‐Schmidt, K. U., & Schraermeyer, U. (2008) · Retina · doi:10.1097/iae.0b013e31815e9368 · Cited by 42
Cited by
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Corneal Neovascularization: An Anti-VEGF Therapy Review
Chang, J.-H., Garg, N. K., Lunde, E., Han, K.-Y., Jain, S., & Azar, D. T. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.007 · Cited by 381
Sato, T., Wada, K., Arahori, H., Kuno, N., Imoto, K., Iwahashi-Shima, C., & Kusaka, S. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.07.005 · Cited by 327
Self-citationOcular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Drug and Gene Delivery to the Back of the Eye: From Bench to Bedside
Rowe-Rendleman, C. L., Durazo, S. A., Kompella, U. B., Rittenhouse, K. D., Di Polo, A., Weiner, A. L., Grossniklaus, H. E., Naash, M. I., Lewin, A. S., Horsager, A., et al. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13707 · Cited by 120
Metadata
- Authors
- Nomoto, H., Shiraga, F., Kuno, N., Kimura, E., Fujii, S., Shinomiya, K., Nugent, A. K., Hirooka, K., & Baba, T.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2009-10-01
- Volume
- 50
- Issue
- 10
- Pages
- 4807
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2072011053
- Cited by
- 269
- References
- 43
- FWCI
- 17.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.